SacVal has been shown to exert a favorable influence on ventricular remodeling and improve clinical outcomes, including cardiovascular death and hospitalization, in patients with heart failure with reduced ejection fraction (HFrEF) and even in partial groups of heart failure with preserved ejection fraction compared with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) (9, 10). Here, ACE is linked to heart failure.